Cointime

Boundless Bio

company

About

Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.

  • 51 - 100

Highlights

Total Funding Amount
$151.40M
Funding Rounds
2
Investors
1
Investments
3

Details

Last Funding Type
Series A
Last Funding Money Raised
$46.40M
Industries
Biotechnology,Health Care,Life Science,Therapeutics
Founded date
Jan 1, 2018
Number Of Employee
51 - 100
Operating Status
Active

Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$151.40M
Boundless Bio has raised a total of $151.40M in funding over 2 rounds. Their latest funding was raised on Apr 28, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 28, 2021 Series B $105M 1 — — Detail
Sep 19, 2019 Series A $46.40M 1 ARCH Venture Partners — Detail

Investments

Number of Investments
Number of Lead Investments
3
0
Boundless Bio has made 3 investments. Their most recent investment was on Jun 25, 2019, when Haus raised 0.
Date Company Name
Round Money Raised Industry Lead Investor
Jun 25, 2019 Haus
Pre-seed — Distillery —
May 30, 2019 Firefly
Series A $30M Advertising Platforms —
Mar 12, 2018 Selfbook
Pre-seed $550K FinTech —

Investors

Number of Lead Investors
Number of Investors
1
1
Boundless Bio is funded by 1 investors. ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners — Series B
Cointime
Содержание
компания